

Investigations of Some Hypoglycemic Drugs by New Analytical Techniques

A Thesis presented by

Mariam Mamdouh Fawzy Tadros

B.SC. Pharmaceutical Sciences, 2010

Master of Pharmaceutical Sciences (Analytical Chemistry), 2015

Faculty of Pharmacy, Ain Shams University

Submitted

For the Partial Fulfillment of PhD Degree in Pharmaceutical Sciences
(Pharmaceutical Analytical Chemistry)

Supervised by

Prof. Dr. Maha Farouk Abdel-Ghany

Professor of Pharmaceutical Analytical Chemistry, Vice Dean for the
Postgraduate Studies Affairs and Scientific Research
& Acting Dean
Faculty of Pharmacy, Ain Shams University

The Late Associate Prof. Dr. Omar Abd-ElAziz Ali Ghonim

Associate Professor of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy, Ain Shams University

Associate Prof. Dr. Miriam Farid Ayad

Associate Professor of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy, Ain Shams University

(2018)

ACKNOWLEDGEMENT

First and foremost, I am thankful to "Allah", the most merciful and the most generous.

*I would like to express my deepest appreciation and sincere gratitude to **Prof. Dr. Maha Farouk Abdel-Ghany**, Professor of Pharmaceutical Analytical Chemistry, Vice Dean for the Postgraduate Studies Affairs and Scientific Research and Acting Dean of Faculty of Pharmacy, Ain Shams University, for suggesting the work, kind supervision, valuable advice and continuous support she kindly offered through all stages of the work.*

*I am deeply grateful to the late **Associate Prof. Dr. Omar Abd-Elaziz Ali Ghonim**, Associate professor of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University for his outstanding guidance, cooperation and guidance throughout my research.*

*I am deeply grateful to **Associate Prof. Dr. Miriam Farid Ayad**, Associate professor of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Ain Shams University for her support during my work in Ain Shams University and I am also grateful to all my colleagues in Ain Shams University.*

*Also I am deeply grateful to my family, my husband and my son (**ADAM**) for their continuous support.*

Mariam Mamdouh

Table of Contents	page
Table of Contents	i
List of Tables	viii
List of Figures	xvi
List of abbreviations	xxiii
Preface	xxvi
English Summary	xxvii

PART (I)

Introduction and Literature Review

I.1.Diabetes Mellitus	1
I.2.Insulin and its analogues	2
I.3.Oral hypoglycemic drugs	3
I.3.1.Sulfonylureas	3
I.3.2.Biguanides	4
I.3.3.Alpha-Glucosidase inhibitors	5
I.3.4.Meglitinides	5
I.3.5.Thiazolidinediones (TZDs)	6
I.3.6.Dipeptidyl peptidase 4 inhibitors (DPP-4)	7
I.3.7.Sodium-glucose linked transporter type 2, (SGLT-2) inhibitors	9
I.4.The Studied Compounds & their Literature review	10
I.4.1. Formula, molecular weight, chemical names and physical properties of the studied drugs	11
I.4.2. Spectrophotometric methods for the studied drugs	12
I.4.3. Chromatographic methods for the studied drugs	20

I.4.4.Electrochemical methods	38
I.4.5.Capillary electrophoresis methods	39

PART (II)

Chromatographic Methods

SECTION (A)

**Enhanced LC-MS/MS Analysis of alogliptin benzoate
and pioglitazone hydrochloride in human plasma,
application to a Pharmacokinetic Study**

II.A.1.Introduction	40
II.A.2.Experimental study	41
II.A.2.1.Instrumentation	41
II.A.2.2.Samples	41
II.A.2.3.Reagents	42
II.A.2.4. Standard Solutions	42
II.A.2.5.Procedure	43
II.A.2.5.1.Chromatographic conditions and mass detection parameters	43
II.A.2.5.2.Sample preparation	43
II.A.2.5.3.Method validation	43
II.A.2.5.4.Application to biological samples (human (volunteers	46
II.A.3.Results and Discussion	47
II.A.3.1.Optimization of procedures and detection parameters	47
II.A.3.2.Method validation	48
II.A.3.3.Pharmacokinetic behavior	50

II.A.3.4.Statistical analysis	51
-------------------------------	----

SECTION (B)

LC-MS/MS Analysis of linagliptin and empagliflozin in bulk and in pharmaceutical formulation

II.B.1.Introduction	67
II.B.2.Experimental study	67
II.B.2.1.Instrumentation	67
II.B.2.2.Samples	67
II.B.2.3.Reagents	68
II.B.2.4.Standard Solutions	68
II.B.2.5.Procedure	69
II.B.2.5.1.Chromatographic conditions and mass detection parameters	69
II.B.2.5.2.Sample preparation	69
II.B.2.5.3.Method Validation	69
II.B.3.Results and Discussion	71
II.B.3.1.Method development	71
II.B.3.2.Method validation	72
II.B.3.3.Statistical analysis	73

SECTION (C)

Stability indicating HPLC assay of Empagliflozin, application to degradation kinetic study

II.C.1.Introduction	87
II.C.2.Experimental study	89
II.C.2.1.Instrumentation	89
II.C.2.2.Samples	90

II.C.2.3.Reagents	90
II.C.2.4.Standard Solutions	90
II.C.2.5.Procedure	91
II.C.2.5.1.Chromatographic conditions	91
II.C.2.5.2.Sample preparation	91
II.C.2.5.3.Method Validation	92
II.C.2.5.4.Forced degradation study	93
II.C.3.Results and Discussion	96
II.C.3.1.Method development	97
II.C.3.2.System suitability tests	98
II.C.3.3.Method validation	98
II.C.3.4.Statistical analysis	100
II.C.3.5. Discussion of the stability indicating study	100
II.C.3.6.Discussion of kinetic behavior	100
II.C.3.7.Discussion of the proposed degradation product	101

SECTION (D)

HPLC simultaneous determination of alogliptin benzoate-pioglitazone hydrochloride combination & linagliptin-empagliflozin combination

II.D.1.Introduction	122
II.D.2.Experimental study	123
II.D.2.1.Instrumentation	123
II.D.2.2.Samples	123
II.D.2.3.Reagents	124
II.D.2.4.Standard Solutions	124

II.D.2.5.Procedure	125
II.D.2.5.1.Chromatographic conditions	125
II.D.2.5.2.Sample preparation	125
II.D.2.5.3.Method Validation	126
II.D.3.Results and Discussion	128
II.D.3.1.Method development	128
II.D.3.2.System suitability tests	129
II.D.3.3.Method validation	130
II.D.3.4.Statistical analysis	132

PART (III)

Spectroscopic Methods

SECTION (A)

Stability indicating spectrofluorimetric assay of Empagliflozin, application to content uniformity testing

III.A.1.Introduction	151
III.A.2.Experimental study	152
III.A.2.1.Instrumentation	152
III.A.2.2.Samples	152
III.A.2.3.Reagents	153
III.A.2.4.Standard Solutions	153
III.A.2.5.Procedure	154
III.A.2.5.1.Sample preparation	154
III.A.2.5.2.Method Validation	154
III.A.2.5.3.Forced degradation study	156
III.A.3.Results and Discussion	158

III.A.3.1.Fluorimetric characteristics of empagliflozin	158
III.A.3.2.Factors affecting fluorescence of empagliflozin	159
III.A.3.3.Method validation	161
III.A.3.4.Statistical analysis	163
III.A.3.5. Discussion of the degradation study	163

SECTION (B)

Spectrophotometric methods for simultaneous determination of alogliptin benzoate-pioglitazone hydrochloride combination & linagliptin-empagliflozin combination

III.B.1.Introduction	180
III.B.2.Experimental study	182
III.B.2.1.Instrumentation	182
III.B.2.2.Samples	182
III.B.2.3.Reagents	183
III.B.2.4.Standard Solutions	183
III.B.2.5.Procedure	184
III.B.2.5.1.Sample preparation	184
III.B.2.5.2.Method Validation	184
III.B.3.Results and Discussion	191
III.B.3.1. Preliminary investigations	191
III.B.3.2.Method validation	192
III.B.3.3.Statistical analysis	194

PART (IV)

Chemometric Methods

**Chemometric methods for simultaneous determination
of alogliptin benzoate-pioglitazone hydrochloride
combination & linagliptin-empagliflozin combination**

IV.1.Introduction	241
IV.2.Experimental study	242
IV.2.1.Instrumentation	242
IV.2.2.Samples	242
IV.2.3.Reagents	243
IV.2.4.Standard Solutions	243
IV.2.5.Procedure	243
IV.2.5.1.Sample preparation	243
IV.2.5.2.Method Validation	244
IV.3.Results and Discussion	245
IV.3.1. Preliminary investigations	245
IV.3.2.Method validation	245
IV.3.3.Statistical analysis	247

PART (V)

General Discussion & References	272
--	-----

List of Tables	page
Table (1): Most commonly used sulphonylureas.	3
Table (2): Most commonly used Biguanide.	4
Table (3): Most commonly used α -Glucosidase inhibitors.	5
Table (4): Most commonly used Meglitinides.	6
Table (5): Most commonly used Thiazolidinedione.	7
Table (6): Most commonly used DPP-4 inhibitors.	7
Table (7): Most commonly used SGLT-2 inhibitors.	9
Table (8): Formula, molecular weight, chemical names and physical properties of the studied drugs.	11
Table (9): Spectrophotometric methods for the studied drugs.	12
Table (10): Chromatographic methods for the studied drugs.	20
Table (11): Results of assay validation of UPLC-MS/MS method for simultaneous determination of alogliptin benzoate and pioglitazone hydrochloride in plasma.	63
Table (12): Results for determination of alogliptin benzoate and pioglitazone hydrochloride in matrix by the proposed UPLC-MS/MS method.	64
Table (13): Precision and stability results of alogliptin benzoate and pioglitazone hydrochloride in matrix by the proposed UPLC-MS/MS method.	65
Table (14): Statistical comparison between the proposed method and the reference method for determination of alogliptin benzoate and pioglitazone hydrochloride.	66
Table (15): Results of assay validation of the proposed UPLC-MS/MS method for determination of linagliptin and empagliflozin in bulk powder.	82

Table (16): Results for determination of linagliptin and empagliflozin in bulk powder by the proposed UPLC-MS/MS method.	83
Table (17): Simultaneous determination of linagliptin and empagliflozin by UPLC-MS/MS method in laboratory prepared mixtures.	84
Table (18): Simultaneous determination of linagliptin and empagliflozin in pharmaceutical dosage form and application of standard addition technique by UPLC-MS/MS method.	85
Table (19): Statistical comparison between the proposed method and the reference method for determination of linagliptin and empagliflozin.	86
Table (20): System suitability tests for HPLC-UV method for the determination of empagliflozin in bulk powder.	115
Table (21): Results of assay validation of HPLC-UV method for determination of empagliflozin in bulk powder.	116
Table (22): Results for determination of empagliflozin in bulk powder by the proposed HPLC-UV method.	117
Table (23): Determination of empagliflozin in pharmaceutical dosage form and application of standard addition technique by HPLC-UV method.	118
Table (24): Statistical comparison between the proposed method and the reference method for determination of empagliflozin.	119
Table (25): Kinetic data of empagliflozin alkaline degradation in presence of 0.5 M NaOH.	120
Table (26): Kinetic data of empagliflozin alkaline degradation in presence of 0.5 M NaOH at 25°C.	121
Table (27): System suitability tests for HPLC-UV methods for simultaneous determination of alogliptin benzoate and pioglitazone hydrochloride.	139
Table (28): System suitability tests for HPLC-UV methods for simultaneous determination of linagliptin and empagliflozin.	140

Table (29): Results of assay validation of HPLC-UV methods for simultaneous determination of alogliptin benzoate and pioglitazone hydrochloride in bulk powder.	141
Table (30): Results of assay validation of HPLC-UV methods for simultaneous determination of linagliptin and empagliflozin in bulk powder.	142
Table (31): Results for simultaneous determination of alogliptin benzoate and pioglitazone hydrochloride in bulk powder by the proposed HPLC-UV method.	143
Table (32): Results for simultaneous determination of linagliptin and empagliflozin in bulk powder by the proposed HPLC-UV method.	144
Table (33): Simultaneous determination of alogliptin benzoate and pioglitazone hydrochloride by the HPLC-UV method in laboratory prepared mixtures.	145
Table (34): Simultaneous determination of linagliptin and empagliflozin by the HPLC-UV method in laboratory prepared mixtures.	146
Table (35): Simultaneous determination of alogliptin benzoate and pioglitazone hydrochloride in pharmaceutical dosage form and application of standard addition technique by HPLC-UV method.	147
Table (36): Simultaneous determination of linagliptin and empagliflozin in pharmaceutical dosage form and application of standard addition technique by HPLC-UV method.	148
Table (37): Statistical comparison between the proposed method and the reference method for determination of alogliptin benzoate and pioglitazone hydrochloride.	149
Table (38): Statistical comparison between the proposed method and the reference method for determination of linagliptin and empagliflozin.	150
Table (39): Results of assay validation of spectrofluorimetric method for determination of empagliflozin in bulk powder.	175

Table (40): Results for determination of empagliflozin in bulk powder by the proposed spectrofluorimetric method.	176
Table (41): Determination of empagliflozin in pharmaceutical dosage form and application of standard addition technique by spectrofluorimetric method.	177
Table (42): Results of content uniformity testing of Jardiance [®] tablets using the spectrofluorimetric method.	178
Table (43): Statistical comparison between the proposed method and the reference method for determination of empagliflozin.	179
Table (44): Results of assay validation of (RTS coupled with ERTS) and (SPS coupled with CM) methods for determination of alogliptin benzoate and pioglitazone hydrochloride in bulk powder.	219
Table (45): Results of assay validation of (RTS coupled with ERTS) and (SPS coupled with CM) methods for determination of empagliflozin and linagliptin in bulk powder.	220
Table (46): Results of assay validation of MC method for determination of alogliptin benzoate and pioglitazone hydrochloride in bulk powder.	221
Table (47): Results of assay validation of MC method for determination of empagliflozin and linagliptin in bulk powder.	222
Table (48): Results for determination of alogliptin benzoate and pioglitazone hydrochloride by (RTS coupled with ERTS) and (SPS coupled with CM) methods in bulk powder.	223
Table (49): Results for determination of empagliflozin and linagliptin by (RTS coupled with ERTS) and (SPS coupled with CM) methods in bulk powder.	224
Table (50): Results for determination of alogliptin benzoate and pioglitazone hydrochloride by MC method in bulk powder.	225
Table (51): Results for determination of empagliflozin and linagliptin by MC method in bulk powder.	226